/

Qilian International Holding Group Limited

QLI US

QLI USQilian International Holding Group Limited

FIGI: BBG00QRWPVY9

Next Earnings

September 29

Ex-Dividend Date

February 27

Dividend Date

March 6

Held by Insiders

77.45%

Held by Institutions

0.08%

Short % of Float

0.01%

YTD Yield

-35.29%

Capital Structure

USD

•

in mil. unless spec.

Mar'22

Sep'22

Mar'23

ST Debt

12,345

LT Borrowings

12,345

LT Finance Leases

12,345

Preferred Equity and Hybrid Capital

12,345

Shares Outstanding

12,345

Market Capitalization

12,345

Working Capital

USD

•

in mil. unless spec.

Mar'22

Sep'22

Mar'23

Total Current Assets

12,345

Cash, Cash Equivalents & STI

12,345

Accounts Receivable, Net

12,345

Inventories

12,345

Total Current Liabilities

12,345

Payables & Accruals

12,345

ST Debt

12,345

Deferred Revenue

12,345

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

12,345

Net Income, GAAP

12,345

Free Cash Flow

12,345

Total Cash Common Dividend

12,345

Total Equity

12,345

Quarterly Revenue

USD

•

in mil. unless spec.

Year

2021

12,345

- -

12,345

2022

12,345

- -

12,345

2023

12,345

- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

- -

12,345

2022

12,345

- -

12,345

2023

12,345

- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

- -

12,345

2022

12,345

- -

12,345

2023

12,345

- -

Company Description

CEO: Mr. Zhanchang Xin
Full Time Employees: 345
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: Jiuquan Economic and Technological Development Zone Jiuquan China 735000
Website: ir.qlsyy.net
Business: Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Company Description

CEO: Mr. Zhanchang Xin
Full Time Employees: 345
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Address: Jiuquan Economic and Technological Development Zone Jiuquan China 735000
Website: ir.qlsyy.net
Business: Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Next Earnings

September 29

Ex-Dividend Date

February 27

Dividend Date

March 6

Held by Insiders

77.45%

Held by Institutions

0.08%

Short % of Float

0.01%

YTD Yield

-35.29%

Capital Structure

USD

•

in mil. unless spec.

Mar'22

Sep'22

Mar'23

ST Debt

12,345

LT Borrowings

12,345

LT Finance Leases

12,345

Preferred Equity and Hybrid Capital

12,345

Shares Outstanding

12,345

Market Capitalization

12,345

Working Capital

USD

•

in mil. unless spec.

Mar'22

Sep'22

Mar'23

Total Current Assets

12,345

Cash, Cash Equivalents & STI

12,345

Accounts Receivable, Net

12,345

Inventories

12,345

Total Current Liabilities

12,345

Payables & Accruals

12,345

ST Debt

12,345

Deferred Revenue

12,345

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

12,345

Net Income, GAAP

12,345

Free Cash Flow

12,345

Total Cash Common Dividend

12,345

Total Equity

12,345

Quarterly Revenue

USD

•

in mil. unless spec.

Year

2021

12,345

- -

12,345

2022

12,345

- -

12,345

2023

12,345

- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

- -

12,345

2022

12,345

- -

12,345

2023

12,345

- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

2021

12,345

- -

12,345

2022

12,345

- -

12,345

2023

12,345

- -

Qilian International Holding Group Limited

QLI US

0.79

Qilian International Holding Group Limited

QLI US

Company Description

0.79

Company Description